SM08502介导的β-卡铁因抑制与olaparib协同作用,以抑制瘤进展
Bradley R Corr1, Elizabeth R Woodruff2, Tomomi M Yamamoto2
1Division of Gynecologic Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado.
Cancer research communications
|December 4, 2025
概括
一种新型药物SM08502 (cirtuvivint),与PARP抑制剂 (PARPi) 结合,在卵巢癌模型中显示出克服对PARPi治疗的抗性. 这种组合疗法减少了瘤的进展,并通过准WNT信号和重塑瘤免疫微环境来改善存活率.
科学领域:
- 在瘤学瘤学.
- 癌症治疗方法 癌症治疗方法
- 分子生物学分子生物学
背景情况:
- PARP 抑制剂 (PARPi) 在治疗BRCA1/2-突变高度血清癌 (HGSC) 中有效.
- PARPi 耐药性是一个重大的临床挑战,限制了晚期卵巢癌患者的治疗选择.
- 较高的WNT信号传递有助于PARPi耐药性,但由于不良事件,直接向是困难的.
研究的目的:
- 评估SM08502 (cirtuvivint),一种间接的WNT抑制剂,与PARPi结合,以克服HGSC中的PARPi耐药性.
- 研究SM08502在耐药模型中影响WNT/TCF转录活性,细胞活力和DNA损伤的机制.
- 评估SM08502和olaparib联合治疗在PARPi耐药卵巢癌的临床前模型中的疗效.
主要方法:
- 在多个耐PARPiHGSC模型中测试SM08502与PARPi结合.
- 评估TCF转录活性,差异基因表达和拼接.
- 使用多谱免疫组织化学 (IHC) 在体内分析瘤微环境.
- 评估瘤进展,免疫微环境重塑和免疫受损和免疫完整模型中的生存.
主要成果:
- 在耐PARPi模型中,SM08502抑制了WNT/TCF转录活性,降低了细胞活力,并诱导了DNA损伤.
- 在体内,SM08502和olaparib的组合显著降低了疾病的进展.
- 瘤免疫微环境被重塑,PD-1和PD-L1.1的表达减少.
- 组合疗法在PARPi耐药HGSC的临床前模型中延长了生存时间.
结论:
- 作为间接WNT抑制剂,SM08502显示出克服PARPi耐药性的潜力.
- 与PARPi (olaparib) 的SM08502的组合提供了一个有前途的策略来治疗抗PARPi的卵巢癌.
- 这种方法需要对耐药HGSC.患者进行进一步的临床研究.
相关概念视频
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Cancer-Critical Genes II: Tumor Suppressor Genes
9.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K
Interactions Between Signaling Pathways
7.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K


